Prepare for the arrival of Priligy

Affiliate news published: June 29th 2009

The first ever oral premature ejaculation drug has completed the next stage on its journey to being released worldwide. Priligy is already available in Finland and Sweden, and pending further approvals, will be available across Europe and beyond by the end of the year. And when Priligy is fully approved and becomes available in the UK and US, our affiliates will be the first to know.

Priligy will be the first prescription drug to treat premature ejaculation ever created. It’s being marketed by Janssen-Cilag, a division of Janssen Pharmaceutical, who have already had great success marketing and selling the drug in Finland and Sweden so far. This revolutionary new treatment uses the active ingredient dapoxetine, which works by inhibiting the neuronal reuptake of serotonin. This inhibits the potency of serotonin, giving men a greater ability to control their ejaculation and enjoy a healthier, more fulfilling sex life.

Priligy has been hugely successful in clinical trials, elongating sexual performance by an average of 200 - 300%. Patients taking Priligy reported significant improvements in their sexual performance, enjoying greater ejaculation control, greater satisfaction during intercourse and an increase in intra-vaginal ejaculatory latency time. One of the other great benefits is that the side effects are very mild and were experienced in only a very small number patients, and for only a couple of hours after taking the drug for the first time.

Premature ejaculation falls under the category of male sexual health along with impotence. The two conditions are very different, but the similarities should make it easy for affiliates to fit Priligy within their existing impotence treatment marketing strategy. Although only available in Finland and Sweden now, it’s already been approved for sale in Austria, Germany, Spain, Italy and Portugal. Priligy is going to be huge, make sure you’re ready for it.